Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01657942 · ClinicalTrials.gov registry record · NA
Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT01657942: Completed NA study, sponsored by InSightec.
NCT01657942 is a NA study that has completed, run by InSightec. The registered enrollment target is 101 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01657942, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.
Primary Outcome
The cumulative sum of adverse events was followed through Month 12 of the study.
Interventions
- DEVICE ExAblate MR Guided Focused Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-10 |
| Est. Completion | 2021-05 |
| Phase | NA |
What the finished NCT01657942 record still lists
NCT01657942 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which ExAblate MR Guided Focused Ultrasound is the first listed.
NCT01657942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01657942 about?
NCT01657942 is a clinical study titled "Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions". The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety a...
What is the current status of trial NCT01657942?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2013-10. Estimated completion is 2021-05.
What interventions are being tested in trial NCT01657942?
The interventions under investigation include: ExAblate MR Guided Focused Ultrasound (DEVICE).
Who is sponsoring clinical trial NCT01657942?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01657942's enrollment target sits among peer trials
101 840th of 2000 higher than 1,161 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia